Moreover, the mutational status of the cell lines used in this study need to be considered and further validations of DOT1L and menin inhibitors on patient-derived OC models and xenografts are necessary to confirm the beneficial effect of the drug combination in clinically relevant cancer models. Here, DOT1L is linked to cancer.